Frequent biological association of Merkel cell polyomavirus with Merkel cell carcinomas Abstract #69

Introduction: Merkel cell polyomavirus (MCPyV) DNA has been detected by PCR in 75–100% of Merkel cell carcinomas (MCC), an aggressive neuroendocrine skin cancer. MCPyV is a 5.4 kb DNA virus that expresses tumor (T) antigen in tumor tissues.
Aim(s): To analyze which subset of MCC is biologically associated with MCPyV using various viral detection methods.
Materials and methods: Genomic DNA isolated from paraffin-embedded tissue of 61 MCC was analyzed by MCPyV-specific PCR. Using a 5kb MCPyV DNA probe, the physical status of MCPyV was determined by fluorescence in situ hybridization (FISH) using tyramide signal amplification and ApoTome microscopy. Expression of large T antigen was assessed by immunohistochemistry (IHC) using monoclonal antibody CM2B4 (kindly provided by Y. Chang).
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Ernst-Jan M Speel

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1129 Expression and Clinical Significance of Merkel Cell Polyomavirus Large T Antigen in Merkel Cell Carcinoma
Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer that is often associated with Merkel cell polyomavirus (MCPyV) infection. MCPyV expression and its relationship with clinical features and prognosis in MCC remain unclear.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Pathology, grading, staging
Presenting Author: Vera Delektorskaya
#1402 Merkel Cell Carcinoma of Lymph Node Without Skin Primary Can - and Should - Be Distinguished from Others Metastatic Neuroendocrine Carcinoma
Introduction: Merkel cell carcinoma of lymph node without primary tumour (MCCNWP) is a rare tumour which can be misinterpreted as lymph node metastasis (LNM) from a high-grade neuroendocrine carcinoma (NEC) on histological examination. However, this distinction is crucial for therapeutic management.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Prof. Serge Guyetant
#1726 A Long-Term Complete Response (CR) of Avelumab in Patient (pt) with Advanced Merkel Cell Carcinoma (MCC)
Introduction: MCC is a rare and aggressive cutaneous neuroendocrine cancer linked to exposure to the Merkel Polyomavirus (MCPyV). Cisplatin and VP16 chemo may be an effective treatment for metastatic MCC, but responses are often transient. The blockade of programmed death 1 (PD-1) immune inhibitory pathway by avelumab, an anti-PD-L1 checkpoint inhibitor, is being investigated in solid neoplasms. This strategy can also be of interest in MCC because these tumors often express PD-L1
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: MD Sara Pusceddu
#2148 Tumor Microenvironment in Merkel Cell Carcinoma: Association with Merkel Cell Polyomavirus and Clinico-Pathological Features in a Retrospective Cohort Study
Introduction: MCC is a rare and aggressive skin cancer with a neuroendocrine phenotype.Association between MCC and Polyomavirus is known.PD-1 and PD-L1 have recently become key players in the therapeutic landscape.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Biomarkers
Presenting Author: doctor Nadia Birocco
#2297 Merkel Cell Carcinomas in New Zealand: Virus or Ultra Violet?
Introduction: Merkel Cell Carcinoma (MCC) is a rare Neuroendocrine skin tumour. MCC behavior is more aggressive than the more common Melanoma, with treatments often restricted to surgery or radiotherapy, although immunotherapy holds promise overseas. In 2008, a USA study identified an oncogenic polyomavirus (MCPyV) present in eight of ten tested MCC tumours. Studies from across Europe and the USA confirmed MCPyV presence in ~80% of all MCCs. However, a cohort from Australia found a rate of just 24%, suggesting an alternative mechanism; ultra violet (UV) exposure was suspected and later confirmed using genomic mutational signature analysis. Are these are two separate diseases, requiring different clinical management strategies for best patient outcomes?
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Tamsin Robb
Authors: Robb T, Woodhouse B, Parker K, Miller R, ...